Health-related quality of life in adolescent patients with hepatitis C genotype 1 treated with Sofosbuvir and Ledipasvir

Journal of Pediatric Gastroenterology and Nutrition

Volumn 66, Issue 1, 2018, Pages 112-116

  Younossi, Zobair M ^a,b   Stepanova, Maria ^c   Balistreri, William ^d   Schwarz, Kathleen ^e   Murray, Karen F ^f   Rosenthal, Philip ^g   Bansal, Sanjay ^h   Hunt, Sharon ^c  

^a INOVA FAIRFAX HOSPITAL   (United States)

^b BETTY AND GUY BEATTY CENTER FOR INTEGRATED RESEARCH   (United States)

^c Center for Outcomes Research in Liver Diseases   (United States)

^d CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f SEATTLE CHILDREN S HOSPITAL   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

Interferon; Pediatric patients; Quality of life; Ribavirin; School functioning

Indexed keywords

LEDIPASVIR PLUS SOFOSBUVIR; ANTIVIRUS AGENT; BENZIMIDAZOLE DERIVATIVE; FLUORENE DERIVATIVE; LEDIPASVIR, SOFOSBUVIR DRUG COMBINATION; URIDINE PHOSPHATE;

ADOLESCENT; ANTIVIRAL THERAPY; ANXIETY DISORDER; ARTICLE; CAREGIVER; CHILD; CHRONIC HEPATITIS C; FEMALE; FOLLOW UP; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; PANIC; PRIORITY JOURNAL; QUALITY OF LIFE; QUALITY OF LIFE ASSESSMENT; SELF REPORT; SUSTAINED VIROLOGIC RESPONSE; TREATMENT DURATION; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; HEALTH STATUS INDICATOR; MULTICENTER STUDY; PROSPECTIVE STUDY; TREATMENT OUTCOME;

ADOLESCENT; ANTIVIRAL AGENTS; BENZIMIDAZOLES; CAREGIVERS; CHILD; FEMALE; FLUORENES; FOLLOW-UP STUDIES; HEALTH STATUS INDICATORS; HEPATITIS C, CHRONIC; HUMANS; MALE; PROSPECTIVE STUDIES; QUALITY OF LIFE; SELF REPORT; TREATMENT OUTCOME; URIDINE MONOPHOSPHATE;

EID: 85039710637     PISSN: 02772116     EISSN: 15364801     Source Type: Journal    
DOI: 10.1097/MPG.0000000000001754     Document Type: Article

References (37)

1. Denniston MM, Jiles RB, Drobeniuc J, et al. Chronic hepatitis C virus infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010. Ann Intern Med 2014;160: 293-300.
2. El-Shabrawi MH, Kamal NM. Burden of pediatric hepatitis C. World J Gastroenterol 2013;19: 7880-8.
3. Robinson JL, Doucette K. The natural history of hepatitis C virus infection acquired during childhood. Liver Int 2012;32: 258-70.
4. Delgado-Borrego A, Healey D, Negre B, et al. Influence of body mass index on outcome of pediatric chronic hepatitis C virus infection. J Pediatr Gastroenterol Nutr 2010;51: 191-7.
5. Indolfi G, Bartolini E, Serranti D, et al. Hepatitis C in children coinfected with human immunodeficiency virus. J Pediatr Gastroenterol Nutr 2015;61: 393-9.
6. Younossi I, Weinstein A, Stepanova M, et al. Mental and emotional impairment in patients with hepatitis C is related to lower work productivity. Psychosomatics 2016;57: 82-8.
7. Spiegel BM, Younossi ZM, Hays RD, et al. Impact of hepatitis C on health related quality of life: A systematic review and quantitative assessment. Hepatology 2005;41: 790-800.
8. Kallman J, O'Neil MM, Larive B, et al. Fatigue and health-related quality of life (HRQOL) in chronic hepatitis C virus infection. Dig Dis Sci 2007;52: 2531-9.
9. Boscarino JA, Lu M, Moorman AC, et al. Predictors of poor mental and physical health status among patients with chronic hepatitis C infection: The chronic hepatitis cohort study (CHeCS). Hepatology 2015;61: 802-11.
10. Younossi ZM, Stepanova M, Nader F, et al. The patient's journey with chronic hepatitis C from interferon plus ribavirin to interferon- And ribavirin-free regimens: A study of health-related quality of life. Aliment Pharmacol Ther 2015;42: 286-95.
11. Nydegger A, Srivastava A, Wake M, et al. Health-related quality of life in children with hepatitis C acquired in the first year of life. J Gastroenterol Hepatol 2008;23: 226-30.
12. Murray KF, Rodrigue JR, González-Peralta RP, et al. Design of the PEDS-C trial: Pegylated interferon +/- ribavirin for children with chronic hepatitis C viral infection. Clin Trials 2007;4: 661-73.
13. Hassanein T, Cooksley G, Sulkowski M, et al. The impact of peginterferon alfa-2a plus ribavirin combination therapy on health-related quality of life in chronic hepatitis C. J Hepatol 2004;40: 675-81.
14. Lam BP, Jeffers T, Younoszai Z, et al. The changing landscape of hepatitis C virus therapy: Focus on interferon-free treatment. Therap Adv Gastroenterol 2015;8: 298-312.
15. Younossi ZM, Stepanova M, Afdhal N, et al. Improvement of healthrelated quality of life and work productivity in chronic hepatitis C patients with early and advanced fibrosis treated with ledipasvir and sofosbuvir. J Hepatol 2015;63: 337-45.
16. Younossi Z, Henry L. Systematic review: Patient-reported outcomes in chronic hepatitis C-The impact of liver disease and new treatment regimens. Aliment Pharmacol Ther 2015;41: 497-520.
17. Younossi ZM, Stepanova M, Sulkowski M, et al. Sofosbuvir and ribavirin for treatment of chronic hepatitis C in patients coinfected with hepatitis C virus and HIV: The impact on patient-reported outcomes. J Infect Dis 2015;212: 367-77.
18. Younossi ZM, Stepanova M, Sulkowski M, et al. Sofosbuvir and ledipasvir improve patient-reported outcomes in patients co-infected with hepatitis C and human immunodeficiency virus. J Viral Hepat 2016;23: 857-65.
19. Younossi ZM, Park H, Gordon SC, et al. Real-world outcomes of ledipasvir/sofosbuvir in treatment-naive patients with hepatitis C. Am J Manag Care 2016;22 (6 spec No): SP205-11.
20. Younossi ZM, Stepanova M, Henry L, et al. An in-depth analysis of patient-reported outcomes in patients with chronic hepatitisCtreated with different anti-viral regimens. Am J Gastroenterol 2016;111: 808-16.
21. Younossi ZM, Stepanova M, Feld J, et al. Sofosbuvir/velpatasvir improves patient-reported outcomes in HCV patients: Results from ASTRAL- 1 placebo-controlled trial. J Hepatol 2016;65: 33-9.
22. Younossi ZM, Stepanova M, Chan HL, et al. Patient-reported outcomes in Asian patients with chronic hepatitis C treated with ledipasvir and sofosbuvir. Medicine (Baltimore) 2016;95: E2702.
23. Younossi ZM, Stepanova M, Nader F, et al. Patient-reported outcomes of elderly adults with chronic hepatitis C treated with interferon- And ribavirin-free regimens. J Am Geriatr Soc 2016;64: 386-93.
24. Gerber L, Estep M, Stepanova M, et al. Effects of viral eradication with ledipasvir and sofosbuvir, with or without ribavirin, on measures of fatigue in patients with chronic hepatitis C virus infection. Clin Gastroenterol Hepatol 2016;14: 156-64.
25. Younossi ZM, Stepanova M, Pol S, et al. The impact of ledipasvir/sofosbuvir on patient-reported outcomes in cirrhotic patients with chronic hepatitis C: The SIRIUS study. Liver Int 2016;36: 42-8.
26. Younossi ZM, Stepanova M, Zeuzem S, et al. Patient-reported outcomes assessment in chronic hepatitis C treated with sofosbuvir and ribavirin: The VALENCE study. J Hepatol 2014;61: 228-34.
27. Younossi ZM, Stepanova M, Marcellin P, et al. Treatment with ledipasvir and sofosbuvir improves patient-reported outcomes: Results from the ION-1, -2, and -3 clinical trials. Hepatology 2015;61: 1798-808.
28. Younossi Z, Henry L. The impact of the new antiviral regimens on patient reported outcomes and health economics of patients with chronic hepatitis C. Dig Liver Dis 2014;46(suppl 5): S186-96.
29. Balistreri WF, Murray KF, Rosenthal P, et al. The safety and effectiveness of ledipasvir-sofosbuvir in adolescents 12 to 17 years old with hepatitis C virus genotype 1 infection. Hepatology 2017;66: 371-8.
30. Varni JW, Burwinkle TM, Seid M. The PedsQL 4.0 as a school population health measure: Feasibility, reliability, and validity. Qual Life Res 2006;15: 203-15.
31. Forrest CB, Tucker CA, Ravens-SiebererU, et al. Concurrent validity of the PROMIS1pediatricglobalhealthmeasure.QualLifeRes2016;25: 739-51.
32. Goldfield GS, Cameron JD, Murray M, et al. Screen time is independently associated with health-related quality of life in overweight and obese adolescents. Acta Paediatr 2015;104: E448-54.
33. Maskell J, Newcombe P, Martin G, et al. Psychosocial functioning differences in pediatric burn survivors compared with healthy norms. J Burn Care Res 2013;34: 465-76.
34. Forton DM, Thomas HC, Murphy CA, et al. Hepatitis C and cognitive impairment in a cohort of patients with mild liver disease. Hepatology 2002;35: 433-9.
35. Ashrafi M, Modabbernia A, Dalir M, et al. Predictors of mental and physical health in non-cirrhotic patients with viral hepatitis: A case control study. J Psychosom Res 2012;73: 218-24.
36. Barboza KC, Salinas LM, Sahebjam F, et al. Impact of depressive symptoms and hepatic encephalopathy on health-related quality of life in cirrhotic hepatitis C patients. Metab Brain Dis 2016;31: 869-80.
37. Fábregas BC, DeAvila RE, Faria MN, et al. Health related quality of life among patients with chronic hepatitis C: A cross-sectional study of sociodemographic, psychopathological and psychiatric determinants. Braz J Infect Dis 2013;17: 633-9.